LetterLetter
Fibroblast Growth Factor 23 Levels in Pulmonary Involvement Associated With Systemic Sclerosis: A Proof-of-concept Study
Luis M. Amezcua-Guerra, Mauricio Mora-Ramirez, Gonzalo Vancini, Valentín Jimenez-Rojas and Ricardo Márquez-Velasco
The Journal of Rheumatology March 2022, jrheum.211156; DOI: https://doi.org/10.3899/jrheum.211156
Luis M. Amezcua-Guerra
Immunology Department, Instituto Nacional de Cardiología Ignacio Chavez; Health Care Department, Universidad Autónoma Metropolitana–Xochimilco, Mexico City, Mexico. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.M. Amezcua-Guerra, Instituto Nacional de Cardiología, Juan Badiano 1, Sección XVI, 14080 Tlalpan, Mexico City, Mexico. Email: lmamezcuag@gmail.com.
Mauricio Mora-Ramirez
Immunology Department, Instituto Nacional de Cardiología Ignacio Chavez; Health Care Department, Universidad Autónoma Metropolitana–Xochimilco, Mexico City, Mexico. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.M. Amezcua-Guerra, Instituto Nacional de Cardiología, Juan Badiano 1, Sección XVI, 14080 Tlalpan, Mexico City, Mexico. Email: lmamezcuag@gmail.com.
Gonzalo Vancini
Immunology Department, Instituto Nacional de Cardiología Ignacio Chavez; Health Care Department, Universidad Autónoma Metropolitana–Xochimilco, Mexico City, Mexico. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.M. Amezcua-Guerra, Instituto Nacional de Cardiología, Juan Badiano 1, Sección XVI, 14080 Tlalpan, Mexico City, Mexico. Email: lmamezcuag@gmail.com.
Valentín Jimenez-Rojas
Immunology Department, Instituto Nacional de Cardiología Ignacio Chavez; Health Care Department, Universidad Autónoma Metropolitana–Xochimilco, Mexico City, Mexico. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.M. Amezcua-Guerra, Instituto Nacional de Cardiología, Juan Badiano 1, Sección XVI, 14080 Tlalpan, Mexico City, Mexico. Email: lmamezcuag@gmail.com.
Ricardo Márquez-Velasco
Immunology Department, Instituto Nacional de Cardiología Ignacio Chavez; Health Care Department, Universidad Autónoma Metropolitana–Xochimilco, Mexico City, Mexico. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. L.M. Amezcua-Guerra, Instituto Nacional de Cardiología, Juan Badiano 1, Sección XVI, 14080 Tlalpan, Mexico City, Mexico. Email: lmamezcuag@gmail.com.
Abstract
Systemic sclerosis (SSc) is a devastating disease associated with lung involvement, primarily interstitial lung disease (ILD) and pulmonary hypertension (PH).1 Although computed tomography (CT) and right heart catheterization accurately identify cardiopulmonary injury,2 their high cost and technical complexity make them inaccessible to most nonspecialized health centers. Thus, the timely detection of lung involvement remains a challenge in real-world settings.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Fibroblast Growth Factor 23 Levels in Pulmonary Involvement Associated With Systemic Sclerosis: A Proof-of-concept Study
Luis M. Amezcua-Guerra, Mauricio Mora-Ramirez, Gonzalo Vancini, Valentín Jimenez-Rojas, Ricardo Márquez-Velasco
The Journal of Rheumatology Mar 2022, jrheum.211156; DOI: 10.3899/jrheum.211156
Fibroblast Growth Factor 23 Levels in Pulmonary Involvement Associated With Systemic Sclerosis: A Proof-of-concept Study
Luis M. Amezcua-Guerra, Mauricio Mora-Ramirez, Gonzalo Vancini, Valentín Jimenez-Rojas, Ricardo Márquez-Velasco
The Journal of Rheumatology Mar 2022, jrheum.211156; DOI: 10.3899/jrheum.211156